相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial
Dietrich W. Beelen et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party
Jesus Duque-Afonso et al.
BONE MARROW TRANSPLANTATION (2022)
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
Juergen Finke et al.
BONE MARROW TRANSPLANTATION (2022)
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
Jesus Duque-Afonso et al.
BONE MARROW TRANSPLANTATION (2021)
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2021)
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Betul Oran et al.
TRANSPLANTATION AND CELLULAR THERAPY (2021)
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study
Federica Sora et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?
Stefan O. Ciurea et al.
BLOOD (2020)
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Alexandros Spyridonidis et al.
BONE MARROW TRANSPLANTATION (2020)
History of hematopoietic cell transplantation: challenges and progress
Noa Granot et al.
HAEMATOLOGICA (2020)
Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
Francesco Saraceni et al.
ONCOTARGET (2018)
Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning
Jesus Duque-Afonso et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity
Mary Eapen et al.
BLOOD ADVANCES (2018)
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT
Rebecca A. Marsh et al.
BLOOD (2016)
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi et al.
LANCET ONCOLOGY (2015)
Reduced-Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan for Patients With Acute Myeloid Leukemia: A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Frederic Baron et al.
CANCER (2015)
Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning
Anna Maria Raiola et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies
Paolo Di Bartolomeo et al.
BLOOD (2013)
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
Maria Ester Bernardo et al.
BLOOD (2012)
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen
J. Sanz et al.
BONE MARROW TRANSPLANTATION (2012)
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant
Stefan O. Ciurea et al.
LEUKEMIA & LYMPHOMA (2012)
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT
S. O. Ciurea et al.
BONE MARROW TRANSPLANTATION (2010)
A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation
Hartmut Bertz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies
Reinhard Marks et al.
BLOOD (2008)
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major
Maria Ester Bernardo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan
A. Shimoni et al.
LEUKEMIA (2007)
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
Ignazio Majolino et al.
LEUKEMIA & LYMPHOMA (2007)
Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥ 60 years) with active myeloid malignancies
A Spyridonidis et al.
BLOOD (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia
H Bertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes
JA Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2002)
Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation
R Wäsch et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
